Next Article in Journal
Rare Genetic Diseases with Defects in DNA Repair: Opportunities and Challenges in Orphan Drug Development for Targeted Cancer Therapy
Previous Article in Journal
Heated Intraperitoneal Chemotherapy in the Management of Advanced Ovarian Cancer
Previous Article in Special Issue
p53 Isoforms and Their Implications in Cancer
Article Menu
Issue 9 (September) cover image

Export Article

Open AccessReview
Cancers 2018, 10(9), 297;

The p53 Pathway in Glioblastoma

Department of Microbiology, Immunology & Cancer Biology, University of Virginia, Charlottesville, VA 22908, USA
Department of Neurology, University of Virginia, Charlottesville, VA 22908, USA
The Cancer Center, University of Virginia, Charlottesville, VA 22908, USA
These authors contributed equally to the manuscript.
Author to whom correspondence should be addressed.
Received: 29 June 2018 / Revised: 17 August 2018 / Accepted: 28 August 2018 / Published: 1 September 2018
(This article belongs to the Special Issue p53 Signaling in Cancers)
Full-Text   |   PDF [2441 KB, uploaded 1 September 2018]   |  


The tumor suppressor and transcription factor p53 plays critical roles in tumor prevention by orchestrating a wide variety of cellular responses, including damaged cell apoptosis, maintenance of genomic stability, inhibition of angiogenesis, and regulation of cell metabolism and tumor microenvironment. TP53 is one of the most commonly deregulated genes in cancer. The p53-ARF-MDM2 pathway is deregulated in 84% of glioblastoma (GBM) patients and 94% of GBM cell lines. Deregulated p53 pathway components have been implicated in GBM cell invasion, migration, proliferation, evasion of apoptosis, and cancer cell stemness. These pathway components are also regulated by various microRNAs and long non-coding RNAs. TP53 mutations in GBM are mostly point mutations that lead to a high expression of a gain of function (GOF) oncogenic variants of the p53 protein. These relatively understudied GOF p53 mutants promote GBM malignancy, possibly by acting as transcription factors on a set of genes other than those regulated by wild type p53. Their expression correlates with worse prognosis, highlighting their potential importance as markers and targets for GBM therapy. Understanding mutant p53 functions led to the development of novel approaches to restore p53 activity or promote mutant p53 degradation for future GBM therapies. View Full-Text
Keywords: glioblastoma; wild type p53; mutant p53; gain-of-function glioblastoma; wild type p53; mutant p53; gain-of-function

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Zhang, Y.; Dube, C.; Gibert, M., Jr.; Cruickshanks, N.; Wang, B.; Coughlan, M.; Yang, Y.; Setiady, I.; Deveau, C.; Saoud, K.; Grello, C.; Oxford, M.; Yuan, F.; Abounader, R. The p53 Pathway in Glioblastoma. Cancers 2018, 10, 297.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top